These binding similarities indicate how CCT3833 inhibits both RAF and SRC and we confirm that CCT3833 inhibits both ERK (ppERK; downstream of CRAF) and SFK (ppSFK) phosphorylation in a dose-dependent manner in HCT-116 (CRC), A549 (NSCLC) (Figure 1G) and MIA-PaCa2 (PDAC) cells (Supplementary Figure S1B, available at https://doi.org/10.1016/j.annonc.2020.10.483). Here, SRC is linked to colorectal carcinoma.